March 3, 2026Open Access

Prognostic Value of Systemic Inflammatory Markers in Locally Advanced or Metastatic Melanoma: A Real-World Analysis

Key Points

Improved risk stratification using systemic inflammatory markers enhances treatment strategies in advanced melanoma.
Biomarkers like SII, SIRI, and CONUT show meaningful prognostic value in assessing disease outcomes.
Observational analysis on several indices indicates their reproducibility and accessibility for clinical use.
Incorporating these markers into assessments may support more personalized treatment decisions.

Abstract

SII, SIRI, 6-month SIRI, dynamic SIRI, and CONUT are practical, accessible, and reproducible biomarkers with meaningful prognostic value in advanced melanoma. Incorporating these indices into routine clinical assessment may enhance risk stratification and support more personalized treatment decision-making.

Bookmark

View Full Paper

Cite This Study

Demirel et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75c26c6e9836116a24b1b https://doi.org/https://doi.org/10.3390/cancers18030420

Bookmark

View Full Paper